Abstract
The median survival of all patients with hepatic metastases from colorectal cancer referred to the Sidney Farber Cancer Institute during a five-year period was 12.5 months. Two major factors influenced survival. The first was extent of disease at presentation. The second was the histologic grade of the cancer. The median survival of patients presenting with the least disease, characterized by less than four liver nodules visible on liver scan (n=38), normal liver size on physical examination (n=60), normal liver function test results (n=30), and normal performance status (n=91), was between 18 and 24 months, regardless of treatment. The median survival of those few patients (n=13) who had objective responses to a variety of treatments, most of whom also had minimal disease at presentation, was also 24 months. Patients whose tumors were poorly differentiated or who had abnormal performance status or weight loss of greater than 10 per cent at presentation survived only six months (median). Those with four or more liver nodules, hepatomegaly (greater than 16-cm vertical span on physical examination), or abnormal liver function test results, survived ten, eight, and 12 months (median), respectively. It is concluded that a significant group of patients survived longer than would have been predicted by earlier literature surveys after the diagnosis of colorectal cancer metastatic to the liver. It is suggested that future therapeutic trials, using survival as a measure of response of patients with liver metastases from colorectal cancer, must be prospectively controlled before selection factors can be differentiated from significant therapy effect.
Similar content being viewed by others
References
Rapoport AH, Burleson RL. Survival of patients treated with systemic fluorouracil for hepatic metastases. Surg Gynecol Obstet 1970;130:773–7.
Ariel IM. Systemic 5-fluorouracil in hepatic metastases from primary colon or rectal cancer. NY State J Med 1972;72:1041–4.
Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ. Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1-3-cis(2-chorethyl-1-nitrosourea, and vincristine. J Natl Cancer Inst 1975;54:69–71.
Priestman TJ, Hanham IW. Results of 27 cases with hepatic metastases treated by combination chemotherapy. Br J Cancer 1972;26:466–72.
Cady B, Oberfield RA. Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon. Am J Surg 1974;127:220–7.
Massey WH, Fletcher WS, Judkins MP, Dennis DL. Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters. Am J Surg 1971;121:160–4.
Ansfield FJ, Ramirez G, Skibba JL, Bryan GT, Davis HL Jr, Wirtanen GW. Intrahepatic arterial infusion with 5-fluorouracil. Cancer 1971;28:1147–51.
Mori W, Masuda M, Miyanaga T. Hepatic artery ligation and tumor necrosis in the liver. Surgery 1966;59:359–63.
Almersjö O, Bengmark S, Rundenstram CM, Hafström L, Nilsson LA. Evaluation of hepatic dearterialization in primary and secondary cancer of the liver. Am J Surg 1972;124:5–9.
Fortner JG, Mulcare RJ, Solis A, Watson RC, Golbey RB. Treatment of primary and secondary liver cancer by hepatic artery ligation and infusion chemotherapy. Ann Surg 1973;178:162–72.
Turek-Maischeider M, Kazem I. Palliative irradiation for liver metastases. JAMA 1975;232:625–8.
Wanebo HJ, Semoglou C, Attiyeh F, Stearns MJ Jr. Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 1978;135:81–5.
Foster JH. Survival after liver resection for secondary tumors. Am J Surg 1978;135:389–94.
Foster JH. Survival after liver resection for cancer. Cancer 1970;26:493–502.
Bengmark S, Hafström L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969;23:198–202.
Jaffe BM, Donegan WL, Watson F, Spratt JS Jr. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 1968;127:1–11.
Pestana C, Reitemeier RJ, Moertel CG, Judd ES, Dockery MB. The natural history of carcinoma of the colon and rectum. Am J Surg 1964;108:826–9.
Swinton NW, Samaan S, Rosenthal D. Cancer of the rectum and sigmoid. Surg Clin North Am 1967;47:657–62.
Ramming K, Sparks F, Eilber F, Morton D. Management of hepatic metastases. Semin Oncol 1977;4:71–9.
Zamcheck N, Doos WG, Prudente R, Lurie BB, Gottlieb LS. Prognostic factors in colon carinoma: correlation of serum carcinoembryonic antigen level and tumor histopathology. Hum Pathol 1975;6:31–45.
Mayer RJ, Garnick MB, Steele GD Jr, Zamcheck N. Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer 1978;42:1428–33.
Steele G Jr, Zamcheck N, Wilson RE. Management of colorectal carcinoma after curative resection. In O'Connell T, ed. Controversies in surgical oncology. Boston: GK Hall, 1981:150–5.
Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981;141:586–9.
Author information
Authors and Affiliations
Additional information
Supported by the Brigham Surgical Group, Inc., and National Cancer Institute grant CA 04486.
About this article
Cite this article
Goslin, R., Steele, G., Zamcheck, N. et al. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 25, 749–754 (1982). https://doi.org/10.1007/BF02553304
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02553304